3 Longevity Drugs I QUIT (And the 4 I Take Instead)

Dave Asprey challenges the conventional longevity drug list, explaining why metformin, rapamycin, and statins fail the human data. Metformin may blunt exercise adaptation and deplete vitamin B12. Rapamycin's mouse-study promise collapsed in the 2025 PEARL trial. Statins come with a steep harm-to-benefit ratio and drain mitochondrial CoQ10. Asprey then walks through a 'yes list' of four repurposed pharmaceuticals — tadalafil, SGLT2 inhibitors, acarbose, and low-dose naltrexone — and explains how each supports metabolism, mitochondrial function, and immune regulation.